alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
| (logo) WELLS

           FARGO | **Commercial  Mortgage Servicing**D1050-084,  8th Floor  401 South Tryon St.  Charlotte, NC 28202  1-800-326-1334

 

  |
|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|

 

**ANNUAL STATEMENT OFCOMPLIANCE**

** **

** **

Reference is herebymade to that certain Pooling and Servicing Agreement dated as of June 1, 2015,by and among Morgan Stanley Capital I Inc., as Depositor, Wells Fargo Bank,National Association, as Master Servicer, LNR Partners, LLC, as General SpecialServicer, Wells Fargo Bank, National Association, as Excluded Mortgage LoanSpecial Servicer, Pentalpha Surveillance LLC, as Trust Advisor, WilmingtonTrust, National Association, as Trustee, and Wells Fargo Bank, NationalAssociation, as Certificate Administrator, Certificate Registrar,Authenticating Agent and Custodian with respect to Commercial MortgagePass-Through Certificates Series 2015-C23 (the "Agreement").Capitalized terms used herein not otherwise defined shall have the meaningsassigned in the Agreement.

 

Pursuant to Section13.9 of the Agreement, I, Leslie Hayton, Managing Director of CommercialMortgage Services do hereby certify that:

 

1.           A review of the activities of the Master Servicer during the period fromJanuary 1, 2018 through December 31, 2018 (the “Reporting Period”), and of itsperformance per the Agreement during such period has been made under mysupervision, and

 

2.           To the best of my knowledge, based on such review, the Master Servicer, hasfulfilled all of its obligations under the Agreement in all material respectsthroughout the Reporting Period.

 

 

IN WITNESS WHEREOF,the undersigned has executed this Certificate as of the 28th day ofFebruary 2019.

 

 

/s/ Leslie Hayton

Leslie Hayton 

Managing Director

Wells Fargo Bank

 

 

| Wells Fargo Bank,  N.A. | (logo) Together  we’ll go far |
|-------------------------|-------------------------------------|
IN THE SUPREME COURT OF PENNSYLVANIA

WESTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

ANTONIO DION FERGUSON,

Petitioner :

:

:

:

:

:

:

:

:

:

: No. 358 WAL 2021

Petition for Allowance of Appeal

from the Order of the Superior Court

ORDER

PER CURIAM

AND NOW , this 22nd day of March, 2022

, the Petition for Allowance of Appeal is

DENIED

.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of the Treasury

###### United States Mint

# AGENCY:

United States Mint, Department of the Treasury.

# ACTION:

Notification.

# SUMMARY:

Pursuant to United States Code, Title 31, section 5135(b)(8)(C), the United States Mint announces the Citizens Coinage Advisory Committee (CCAC) public meeting scheduled for March 23, 2010.

*Date:*                         March 23, 2010.                    

*Time:*                         3 p.m. to 5 p.m.                    

*Location:*                         8th Floor Boardroom, United States Mint, 801 9th Street, NW., Washington, DC 20220.                    

*Subject:*                         Review candidate designs for the 2010 American Eagle Platinum Coin Program and discuss the 2009 and 2010 Annual Reports.                    

Interested persons should call 202-354-7502 for the latest update on meeting time and room location.

In accordance with 31 U.S.C. 5135, the CCAC:
      - Advises the Secretary of the Treasury on any theme or design proposals relating to circulating coinage, bullion coinage, Congressional Gold Medals, and national and other medals.
      - Advises the Secretary of the Treasury with regard to the events, persons, or places to be commemorated by the issuance of commemorative coins in each of the five calendar years succeeding the year in which a commemorative coin designation is made.
      - Makes recommendations with respect to the mintage level for any commemorative coin recommended.

# FOR FURTHER INFORMATION CONTACT:

Cliff Northup, United States Mint Liaison to the CCAC; 801 9th Street, NW.; Washington, DC 20220; or call 202-354-7200.

Any member of the public interested in submitting matters for the CCAC's consideration is invited to submit them by fax to the following number: 202-756-6830.

Authority: 31 U.S.C. 5135(b)(8)(C).

Dated: March 5, 2010.

Edmund C. Moy,

Director, United States Mint.

[FR Doc. 2010-5096 Filed 3-9-10; 8:45 am]

BILLING CODE P
#### § 99.105 Recipients of information.

A manufacturer disseminating information on a new use under this part may only disseminate that information to a health care practitioner, a pharmacy benefit manager, a health insurance issuer, a group health plan, or a Federal or State Government agency.
# C_2016475EN.01000302.xml

| 19.12.2016 | EN | Official Journal of the European Union | C 475/3 |
| --- | --- | --- | --- |

19.12.2016

EN

Official Journal of the European Union

C 475/3

---

Judgment of the Court (Fourth Chamber) of 20 October 2016 (request for a preliminary ruling from the Finanzgericht München — Germany) — Josef Plöckl v Finanzamt Schrobenhausen

(Case C-24/15) (1)

1

((Reference for a preliminary ruling - Taxation - Value added tax - Sixth Directive - Article 28c(A)(a) and (d) - Transfer of goods within the European Union - Right to an exemption - Failure to comply with an obligation to provide a VAT identification number issued by the Member State of destination - No specific evidence of tax evasion - Refusal to grant the exemption - Whether permissible))

(2016/C 475/04)

Language of the case: German

Referring court

Referring court

Finanzgericht München

Parties to the main proceedings

Parties to the main proceedings

Applicant: Josef Plöckl

Applicant:

Defendant: Finanzamt Schrobenhausen

Defendant:

Operative part of the judgment

Operative part of the judgment

Article 22(8) of Sixth Council Directive 77/388/EEC of 17 May 1977 on the harmonisation of the laws of the Member States relating to turnover taxes — Common system of value added tax: uniform basis of assessment, as amended by Council Directive 2005/92/EC of 12 December 2005, in the version resulting from Article 28h of that Sixth Directive, and the first subparagraph of Article 28c(A)(a) and Article 28c(A)(d) of that directive must be interpreted as precluding a tax authority of the Member State of origin from refusing to exempt an intra-Community transfer from VAT on the ground that the taxable person has not provided a VAT identification number issued by the Member State of destination, where there is no specific evidence of tax evasion, the goods have been moved to another Member State and the other conditions of exemption from tax are also met.

---

(1)  OJ C 138, 27.4.2015.

1

---
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
FINANCIAL STATEMENTS OF PRO TECH COMMUNICATIONS, INC. FOR THE YEAR ENDED OCTOBER
31, 2000,  AND IS  QUALIFIED  IN ITS  ENTIRETY BY  REFERENCE  TO SUCH  FINANCIAL
STATEMENTS.
</LEGEND>

<CIK>                         0000945481
<NAME>                        Pro Tech Communications, Inc.
<MULTIPLIER>                  1000
<CURRENCY>                    US Dollars

<S>                             <C>
<PERIOD-TYPE>                              Year
<FISCAL-YEAR-END>                          OCT-31-2000
<PERIOD-START>                             NOV-01-1999
<PERIOD-END>                               OCT-31-2000
<EXCHANGE-RATE>                                    1
<CASH>                                       1,070,408
<SECURITIES>                                         0
<RECEIVABLES>                                  421,372
<ALLOWANCES>                                    26,557
<INVENTORY>                                    558,860
<CURRENT-ASSETS>                             2,082,775
<PP&E>                                         278,805
<DEPRECIATION>                                  51,546
<TOTAL-ASSETS>                              18,652,665
<CURRENT-LIABILITIES>                          666,643
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                  1,505,425
<COMMON>                                        28,248
<OTHER-SE>                                  16,472,349
<TOTAL-LIABILITY-AND-EQUITY>                18,652,665
<SALES>                                      1,562,484
<TOTAL-REVENUES>                             1,101,450
<CGS>                                          623,555
<TOTAL-COSTS>                                1,898,845
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                 7,990
<INTEREST-EXPENSE>                              36,592
<INCOME-PRETAX>                               (374,340)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (374,340)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (374,340)
<EPS-BASIC>                                      (0.57)
<EPS-DILUTED>                                    (0.57)




</TABLE>
38795.

#### HICKS v. GENTRY *et al.*

Decided June 1, 1961

Rehearing denied June 20,1961.

*5
      *Hicks & Henderson, Claud M. Hicks, G. Robert Howard,*for plaintiff in error.

*Reed, Ingram A Flournoy, Raymond M. Reed,*contra.

Felton, Chief Judge.

The trial court’s judgment was right for four reasons:

1. The question involved here has been ruled on in *Save-Way Oil Co. v. Thomas,*100 Ga. App. 181 (110 SE2d 681). The rationale of that case and this is that the original lease provides for the exercise of options to renew for two five-year terms. The question is not whether the word “renew” or the word “extend” is used but whether the parties intended a present devise or that a new lease be executed at the end of each five-year term. In the case above cited and in this one the original lease provided for an option as to each of the two renewal periods of five years. If a new lease had been contemplated the provision for the second option would not have been put in the original lease as to the option for the second renewal term because such an agreement in the original lease would not have been necessary. Indeed, the first lease with all of its provisions would have been superseded by a new lease and the new lease would have had to include an option for the second renewal period.

2. Even if a new lease had been in the contemplation of the parties, and if after due notice the landlord was obligated to execute a new lease and refused, the tenant Would have an equitable right to a new lease and would not have to resort to a petition for specific performance for the reason that the tenant’s right to specific performance can be asserted as a defense to a dispossessory proceeding. *Pritchett v. King,*56 Ga. App. 788 (194 SE 44).

3. The landlord honored the first notice under the original lease provision and did not require a new lease, and this conduct is an estoppel against the landlord to assert his right to *6a new lease for the second renewal term as pleaded by the tenant.

4. The most cogent reason why a new lease was not necessary under the facts of this case is one which has evidently been overlooked through the years. Our interpretation of the Supreme Court’s ruling in *Slater v. Kimbro,*91 Ga. 217 (18 SE 296, 44 ASR 19), speaking through Judge Bleckley, is that with or without a notice from the tenant exercising an option of extension or renewal, and even if a renewal contract is contemplated, the landlord cannot deny the tenant the renewal term unless the landlord tenders a renewal contract to the tenant and the tenant refuses to execute it. This ruling seems to take precedence over the ruling in *Walker v. Brooks Simmons Co.,*44 Ga. App. 470, 471 (161 SE 659) and any others to the contrary. The *Walker*case differs from this case, let it be noted, in that, in that case there was no notice and it was simply held that in the absence of notice to exercise a renewal option the mere holding over and paying rent did not effect a contract for a renewal term.

*Judgment in favor of the tenant affirmed.*

*Bell and Hall, JJ., concur.*
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED FINANCIAL STATEMENTS OF ENTREE CORPORATION AS OF AND FOR THE
40 WEEKS ENDED JANUARY 6, 1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          MAR-30-1996
<PERIOD-START>                             OCT-15-1995
<PERIOD-END>                               JAN-06-1996
<CASH>                                            1220
<SECURITIES>                                         0
<RECEIVABLES>                                     8884
<ALLOWANCES>                                     (378)
<INVENTORY>                                       4758
<CURRENT-ASSETS>                                 14740
<PP&E>                                            7455
<DEPRECIATION>                                  (4267)
<TOTAL-ASSETS>                                   19141
<CURRENT-LIABILITIES>                             8907
<BONDS>                                           3810
<COMMON>                                            80
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                      (1721)
<TOTAL-LIABILITY-AND-EQUITY>                     19141
<SALES>                                         182709
<TOTAL-REVENUES>                                182749
<CGS>                                           179218
<TOTAL-COSTS>                                   179218
<OTHER-EXPENSES>                                  3072
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 776
<INCOME-PRETAX>                                  (319)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              (319)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (319)
<EPS-PRIMARY>                                    (.04)
<EPS-DILUTED>                                    (.00)
        

</TABLE>
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.1550 Ultrasonic pulsed doppler imaging system. ( a ) *Identification.* An ultrasonic pulsed doppler imaging system is a device that combines the features of continuous wave doppler-effect technology with pulsed-echo effect technology and is intended to determine stationary body tissue characteristics, such as depth or location of tissue interfaces or dynamic tissue characteristics such as velocity of blood or tissue motion. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.
( b ) *Classification.* Class II.
<TABLE> <S> <C>

<ARTICLE> 9
<LEGEND>
This schedule contains summary financial information extracted from the annual
report on Form 10-K for the fiscal year ended March 31, 1998 and is qualified in
its entirety by reference to such financial statements.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          MAR-31-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                             783
<INT-BEARING-DEPOSITS>                           2,401
<FED-FUNDS-SOLD>                                 6,200
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                     22,868
<INVESTMENTS-CARRYING>                          35,531
<INVESTMENTS-MARKET>                            35,971
<LOANS>                                         58,325
<ALLOWANCE>                                        702
<TOTAL-ASSETS>                                 129,345
<DEPOSITS>                                     104,993
<SHORT-TERM>                                         0
<LIABILITIES-OTHER>                              2,552
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            16
<OTHER-SE>                                      21,784
<TOTAL-LIABILITIES-AND-EQUITY>                 129,345
<INTEREST-LOAN>                                  5,004
<INTEREST-INVEST>                                3,780
<INTEREST-OTHER>                                   609
<INTEREST-TOTAL>                                 9,393
<INTEREST-DEPOSIT>                               4,721
<INTEREST-EXPENSE>                               4,721
<INTEREST-INCOME-NET>                            4,672
<LOAN-LOSSES>                                       42
<SECURITIES-GAINS>                                 109
<EXPENSE-OTHER>                                  3,010
<INCOME-PRETAX>                                  1,888
<INCOME-PRE-EXTRAORDINARY>                       1,888
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     1,097
<EPS-PRIMARY>                                     0.80
<EPS-DILUTED>                                     0.77
<YIELD-ACTUAL>                                    3.79
<LOANS-NON>                                      1,440
<LOANS-PAST>                                       119
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                   660
<CHARGE-OFFS>                                        0
<RECOVERIES>                                         0
<ALLOWANCE-CLOSE>                                  702
<ALLOWANCE-DOMESTIC>                               702
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.9 Limitations of exemptions from section 510(k) of the Federal Food, Drug, and Cosmetic Act (the act). The exemption from the requirement of premarket notification (section 510(k) of the act) for a generic type of class I or II device is only to the extent that the device has existing or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of in vitro diagnostic devices, only to the extent that misdiagnosis as a result of using the device would not be associated with high morbidity or mortality. Accordingly, manufacturers of any commercially distributed class I or II device for which FDA has granted an exemption from the requirement of premarket notification must still submit a premarket notification to FDA before introducing or delivering for introduction into interstate commerce for commercial distribution the device when: ( a ) The device is intended for a use different from the intended use of a legally marketed device in that generic type of device; e.g., the device is intended for a different medical purpose, or the device is intended for lay use where the former intended use was by health care professionals only;
( b ) The modified device operates using a different fundamental scientific technology than a legally marketed device in that generic type of device; e.g., a surgical instrument cuts tissue with a laser beam rather than with a sharpened metal blade, or an in vitro diagnostic device detects or identifies infectious agents by using deoxyribonucleic acid (DNA) probe or nucleic acid hybridization technology rather than culture or immunoassay technology; or
( c ) The device is an in vitro device that is intended: ( 1 ) For use in the diagnosis, monitoring, or screening of neoplastic diseases with the exception of immunohistochemical devices;
( 2 ) For use in screening or diagnosis of familial or acquired genetic disorders, including inborn errors of metabolism;
( 3 ) For measuring an analyte that serves as a surrogate marker for screening, diagnosis, or monitoring life-threatening diseases such as acquired immune deficiency syndrome (AIDS), chronic or active hepatitis, tuberculosis, or myocardial infarction or to monitor therapy;
( 4 ) For assessing the risk of cardiovascular diseases;
( 5 ) For use in diabetes management;
( 6 ) For identifying or inferring the identity of a microorganism directly from clinical material;
( 7 ) For detection of antibodies to microorganisms other than immunoglobulin G (IgG) or IgG assays when the results are not qualitative, or are used to determine immunity, or the assay is intended for use in matrices other than serum or plasma;
( 8 ) For noninvasive testing as defined in § 812.3(k) of this chapter; and
( 9 ) For near patient testing (point of care).
[65 FR 2321, Jan. 14, 2000]